Micafungin

• CAT Number: I002784
• CAS Number: 235114-32-6
• Molecular Formula: C56H71N9O23S
• Molecular Weight: 1270.30
• Purity: ≥95%
• Target: Fungal
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: [5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate
• InChI: InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1
• InChIKey: PIEUQSKUWLMALL-YABMTYFHSA-N
• SMILES: CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O

Micafungin (Cat No.:I002784) is an antifungal medication belonging to the echinocandin class. It is primarily used for the treatment of invasive fungal infections caused by Candida species, including candidemia, esophageal candidiasis, and invasive candidiasis. Micafungin works by inhibiting the synthesis of β(1,3)-D-glucan, an essential component of the fungal cell wall. This disrupts the integrity of the fungal cell wall, leading to cell death. Micafungin is administered intravenously and is generally well-tolerated, with a low risk of drug interactions. It is an important option in the management of serious fungal infections, particularly in patients who are unable to tolerate other antifungal agents.

Reference

1: Shibata Y, Hagihara M, Kato H, Kawasumi N, Hirai J, Nishiyama N, Asai N,
Koizumi Y, Yamagishi Y, Matsuura K, Mikamo H. Caspofungin versus micafungin in
the incidence of hepatotoxicity in patients with normal to moderate liver
failure. J Infect Chemother. 2017 Apr 18. pii: S1341-321X(17)30036-3. doi:
10.1016/j.jiac.2017.02.008. [Epub ahead of print] PubMed PMID: 28431933.
2: Maximova N, Schillani G, Simeone R, Maestro A, Zanon D. Comparison of Efficacy
and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell
Transplant Recipients: A Retrospective Analysis. Adv Ther. 2017 Apr 20. doi:
10.1007/s12325-017-0534-7. [Epub ahead of print] PubMed PMID: 28429246.
3: Guirao-Abad JP, Sánchez-Fresneda R, Alburquerque B, Hernández JA, Argüelles
JC. ROS formation is a differential contributory factor to the fungicidal action
of Amphotericin B and Micafungin in Candida albicans. Int J Med Microbiol. 2017
Apr 4. pii: S1438-4221(16)30361-7. doi: 10.1016/j.ijmm.2017.03.005. [Epub ahead
of print] PubMed PMID: 28412040.
4: Norimatsu Y, Morii D, Kogure A, Hamanaka T, Kuwano Y, Yokozawa T, Oda T. A
case of breakthrough Candida parapsilosis fungemia during micafungin therapy for
a Candida glabrata bloodstream infection. Med Mycol Case Rep. 2017 Mar 23;16:1-3.
doi: 10.1016/j.mmcr.2017.03.002. eCollection 2017 Jun. PubMed PMID: 28377868;
PubMed Central PMCID: PMC5369859.
5: Kovács R, Tóth Z, Nagy F, Daróczi L, Bozó A, Majoros L. Activity of exogenous
tyrosol in combination with caspofungin and micafungin against Candida
parapsilosis sessile cells. J Appl Microbiol. 2017 Mar 21. doi:
10.1111/jam.13452. [Epub ahead of print] PubMed PMID: 28321957.
6: Toyoshima T, Ishibashi KI, Yamanaka D, Adachi Y, Ohno N. Resistance of
Aspergillus fumigatus to Micafungin is Increased by Exogenous β-glucan. Med Mycol
J. 2017;58(1):E39-E44. doi: 10.3314/mmj.16-00029. PubMed PMID: 28250363.
7: Martial LC, Ter Heine R, Schouten JA, Hunfeld NG, van Leeuwen HJ, Verweij PE,
de Lange DW, Pickkers P, Brüggemann RJ. Population Pharmacokinetic Model and
Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Clin Pharmacokinet. 2017 Jan 31. doi: 10.1007/s40262-017-0509-5. [Epub ahead of
print] PubMed PMID: 28144840.
8: Scott LJ. Micafungin: A Review in the Prophylaxis and Treatment of Invasive
Candida Infections in Paediatric Patients. Paediatr Drugs. 2017 Feb;19(1):81-90.
doi: 10.1007/s40272-016-0211-3. Review. PubMed PMID: 28083856.